Copy
Teach Transfer Today

February 2021

Dear Colleagues,

For a tenth consecutive year, U-M ranks No. 1 in research volume among U.S. public universities, according to the latest NSF Report. As we share in the stories below, U-M innovators are working tirelessly to move the results of this research towards the market as promising new technologies, devices, and therapeutics.

Please remember that Giving Blueday is March 10th. If you are looking to support U-M please consider a donation to the Accelerate Blue Fund.

Thank you for your continued support of the University of Michigan’s innovation ecosystem.

Sincerely,

Kelly Sexton, Ph.D.
Associate Vice President for Research - Technology Transfer and Innovation Partnerships
University of Michigan

Donate to U-M Accelerate Blue Fund

Your donation will support a philanthropic investment fund to provide early-stage capital for U-M tech startups. Startups create opportunities for U-M innovators, graduates, and drive economic growth.

Request for Proposals

The Michigan Translational Research and Commercialization (MTRAC) Innovation Hub for Advanced Transportation is accepting research proposals to receive grant funding awards through March 17, 2021.


U-M Startup Oncopia Acquired by Roivant Pharma

Roivant will also provide $15.4 million in research funding to prolific inventor Shaomeng Wang's U-M lab.


World-Class U-M Accelerator Supports Startups

Innovation Manager Diane Bouis shares with us the many ways the accelerator is helping startups be successful.

U-M Startup OncoImmune Acquired by Merck

Acquisition adds to Merck’s suite of clinical programs in response to SARS-CoV-2/COVID-19.


U-M Startup Kinetica Labs  Motion Capture Software

Kinetica Labs is revolutionizing the workplace safety market with a trio of motion capture applications.


Startup Webinar Series Offered by Venture Experts

Partnering with U-M Tech Transfer, OUP invites U-M inventors and entrepreneurs to join their Startup 101 webinar series.

Amgen and U-M Startup EVOQ Enter Collaboration

Amgen and EVOQ will collaborate on preclinical development of novel drugs for autoimmune disorders.